FIT-DNA Shows Modest Advantage Over FIT for CRC Screening in Community Health Centers

Why It Matters

Even a modest lift in colorectal‑cancer screening can translate into earlier detection for high‑risk, underserved populations, but without effective follow‑up the clinical benefit remains limited.

Key Takeaways

• FIT‑DNA increased 90‑day screening to 27.9% vs 22.6% for FIT.
• Uptake remained modest; under one‑third of patients screened by 180 days.
• Follow‑up colonoscopy after abnormal results was low, especially in Los Angeles.
• Hispanic and Spanish‑speaking patients showed higher participation with FIT‑DNA.
• Manufacturer‑run outreach reduced clinic staff burden but did not solve follow‑up gaps.

Pulse Analysis

Colorectal cancer remains the second leading cause of cancer death in the United States, and screening gaps are most pronounced among safety‑net patients served by community health centers (CHCs). Traditional fecal immunochemical testing (FIT) is inexpensive and familiar to primary‑care teams, but its reliance on clinic‑based distribution limits reach in resource‑constrained settings. FIT‑DNA, a newer stool‑based assay with higher sensitivity for advanced lesions, can be mailed directly to patients and is supported by a manufacturer‑run assistance program, positioning it as a potential lever to close the disparity gap.

The recent JAMA Internal Medicine trial compared these two approaches across Boston and Los Angeles CHCs, revealing a modest but statistically significant edge for FIT‑DNA. Screening participation rose to 27.9% at 90 days versus 22.6% for FIT, with the gap widening among Hispanic and Spanish‑speaking cohorts—groups that traditionally face language and insurance barriers. Regional variation was stark: Los Angeles saw a 9‑percentage‑point boost with FIT‑DNA, while Boston’s rates were nearly identical across arms, suggesting that local health‑system factors and kit brand differences can influence outcomes. Despite higher test completion, only 36 of 100 abnormal results led to colonoscopy within six months, underscoring a critical bottleneck in the diagnostic cascade.

For policymakers and health‑system leaders, the findings signal that mailed FIT‑DNA can improve initial screening metrics without adding staff workload, yet it is not a panacea. Effective colorectal‑cancer control will require integrated navigation services that ensure abnormal results translate into timely colonoscopy, especially in regions with limited specialty access. Future research should explore hybrid models that combine manufacturer outreach with community‑based patient navigation, and evaluate cost‑effectiveness given FIT‑DNA’s higher price point. Aligning reimbursement incentives and expanding tele‑health support could amplify the modest gains observed, moving CHCs closer to equitable cancer prevention.